Nuclear receptors: recent drug discovery for cancer therapies
L Zhao, S Zhou, JÅ Gustafsson - Endocrine reviews, 2019 - academic.oup.com
Nuclear receptors (NRs) are transcription factors actively involved in many aspects of human
physiology and pathology, serving as sensors of stimuli, master regulators of downstream …
physiology and pathology, serving as sensors of stimuli, master regulators of downstream …
The Lancet Commission on prostate cancer: planning for the surge in cases
Executive summary Prostate cancer is the most common cancer in men in 112 countries,
and accounts for 15% of cancers. In this Commission, we report projections of prostate …
and accounts for 15% of cancers. In this Commission, we report projections of prostate …
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a …
Background PROpel met its primary endpoint showing statistically significant improvement
in radiographic progression-free survival with olaparib plus abiraterone versus placebo plus …
in radiographic progression-free survival with olaparib plus abiraterone versus placebo plus …
ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer
AJ Armstrong, RZ Szmulewitz, DP Petrylak… - Journal of Clinical …, 2019 - ascopubs.org
PURPOSE Enzalutamide, a potent androgen-receptor inhibitor, has demonstrated
significant benefits in metastatic and nonmetastatic castration-resistant prostate cancer. We …
significant benefits in metastatic and nonmetastatic castration-resistant prostate cancer. We …
Optimum imaging strategies for advanced prostate cancer: ASCO guideline
PURPOSE Provide evidence-and expert-based recommendations for optimal use of
imaging in advanced prostate cancer. Due to increases in research and utilization of novel …
imaging in advanced prostate cancer. Due to increases in research and utilization of novel …
Proposal for systemic-therapy response-assessment criteria at the time of PSMA PET/CT imaging: the PSMA PET progression criteria
In around 20% of men with prostate cancer, metastasis develops during the course of their
disease. Accordingly, discovering and developing new potent treatment strategies for …
disease. Accordingly, discovering and developing new potent treatment strategies for …
Natural compounds targeting nuclear receptors for effective cancer therapy
Human nuclear receptors (NRs) are a family of forty-eight transcription factors that modulate
gene expression both spatially and temporally. Numerous biochemical, physiological, and …
gene expression both spatially and temporally. Numerous biochemical, physiological, and …
Enzalutamide: a review in castration-resistant prostate cancer
LJ Scott - Drugs, 2018 - Springer
Oral enzalutamide (Xtandi®), a second generation androgen receptor inhibitor, is indicated
for the treatment of castration-resistant prostate cancer (CRPC) in numerous countries …
for the treatment of castration-resistant prostate cancer (CRPC) in numerous countries …
Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial
ProBio is the first outcome-adaptive platform trial in prostate cancer utilizing a Bayesian
framework to evaluate efficacy within predefined biomarker signatures across systemic …
framework to evaluate efficacy within predefined biomarker signatures across systemic …
Systemic therapies for metastatic hormone‐sensitive prostate cancer: network meta‐analysis
Objectives To perform a systematic review and network meta‐analysis to compare the
efficacy and safety of currently available treatments for the management of metastatic …
efficacy and safety of currently available treatments for the management of metastatic …